Filing Analysis
Fortress Biotech, Inc. filed an 8-K to announce its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the release of corporate updates and earnings data.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The company issued a press release (Exhibit 99.1) containing financial results and corporate updates.
- Information furnished under Item 2.02 is not deemed 'filed' for purposes of Section 18 liability.
Fortress Biotech, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 17, 2026. The meeting included the election of seven directors and the ratification of KPMG LLP as the company's independent registered public accounting firm.
📋 Key Facts
- The 2026 Annual Meeting was held virtually on June 17, 2026.
- Seven directors were elected to hold office until the 2027 annual meeting or until resignation/removal.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- All seven director candidates received a majority of votes (Total Votes For > Total Votes Against + Abstentions).
- The ratification of KPMG LLP passed with 23,095,864 votes in favor.
Fortress Biotech, Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The disclosure was made via a press release furnished under Item 2.02.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The press release was issued and furnished on May 14, 2026.
- The report was signed by David Jin, Chief Financial Officer.
- The information is furnished under Item 2.02 and is not deemed 'filed' for liability purposes.
Fortress Biotech, Inc. issued a press release on March 31, 2026, to announce its financial results for the fiscal year ended December 31, 2025, and provide a corporate update.
📋 Key Facts
- The filing reports financial results for the year ended December 31, 2025.
- The press release was furnished as Exhibit 99.1 on March 31, 2026.
- The report was signed by David Jin, the Chief Financial Officer.
- The information is furnished under Item 2.02 and is not deemed 'filed' for Section 18 liability purposes.
Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million in gross proceeds. Fortress expects to receive at least $100 million of these proceeds through dividends and the settlement of intercompany debt and expenses.
📋 Key Facts
- Cyprium Therapeutics (80.4% owned by Fortress) sold its PRV for $205 million gross on March 30, 2026.
- Fortress Biotech expects to receive an aggregate of at least $100.0 million from the transaction.
- Cyprium redeemed all of its outstanding 9.375% Perpetual Preferred Stock using the proceeds.
- Cyprium is obligated to pay 20% of the PRV sale proceeds to an institute of the National Institutes of Health (NIH).
- The $100 million expected by Fortress includes pro rata dividends and repayment of intercompany debt, interest, and accrued expenses.
Fortress Biotech's majority-owned subsidiary Cyprium Therapeutics entered into a definitive asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) — originally issued in connection with FDA approval of ZYCUBO® for Menkes disease — for $205 million in cash. The filing simultaneously discloses a Second Amendment to Fortress's existing Oaktree credit facility, which modifies financial covenants contingent on receipt of PRV sale proceeds, including a mandatory $10.0 million loan prepayment. Fortress (80.4% Cyprium owner) expects to receive at least $100 million in aggregate proceeds from Cyprium through dividends and intercompany agreements.
🚩 Red Flags
- Multiple 8-K items filed simultaneously (Items 1.01, 2.03, 8.01) — complexity and interdependence of transactions warrants scrutiny
- Fortress expected proceeds of 'at least $100 million' are substantially less than the $205 million PRV sale price, with significant leakage to NIH (20% of proceeds), Cyprium taxes, preferred stock redemption, and other Cyprium obligations
- Current outstanding Loan balance of ~$29.5 million and covenant structure suggest prior financial stress requiring amended terms
- Second Amendment reduces Minimum Liquidity Amount to just $2.0 million post-monetization — a low floor for a clinical-stage biotech
- Covenant relaxation contingent on deal closing introduces timing and execution risk (HSR clearance still pending)
- Failure to comply with financial covenants triggers event of default with limited cure rights
📋 Key Facts
- Cyprium Therapeutics, Inc. (majority-owned subsidiary, 80.4% owned by Fortress) entered into a PRV Asset Purchase Agreement on February 22, 2026
- Sale price: $205 million in cash, payable at closing
- PRV was issued in connection with FDA approval of ZYCUBO® (copper histidinate/CUTX-101) for Menkes disease in pediatric patients
- Transaction subject to HSR Act antitrust waiting period expiration/termination before closing
- Fortress expects to receive at least $100 million aggregate from Cyprium via dividends and intercompany agreements post-closing
- Key deductions from Cyprium proceeds: 20% of PRV sale proceeds owed to a National Institutes of Health institute, Cyprium tax obligations, redemption of Cyprium's 9.375% Perpetual Preferred Stock, and outstanding obligations
- Second Amendment to Oaktree Credit Agreement also executed February 22, 2026
- Original Oaktree Credit Agreement dated July 25, 2024; $35.0 million initially borrowed; ~$29.5 million currently outstanding; up to $15.0 million additional available
- Second Amendment triggers relaxation of financial covenants (Minimum Net Sales, Capital Raise, Minimum JMC Stake) if Loan balance falls to ≤$15.0 million following the 2026 Cyprium Monetization Event
- All covenants eliminated if outstanding principal balance ≤$10.0 million
- Mandatory $10.0 million prepayment of Loan required upon 2026 Cyprium Monetization Event, plus accrued interest and Yield Protection Premium
- Minimum Liquidity Amount reduced to $2.0 million post-monetization event (if balance ≤$15.0 million)
- Cyprium must repay intercompany advances under the Second Amended and Restated Future Advance Promissory Note upon the monetization event
- Filing covers Items 1.01, 2.03, 8.01, and 9.01
Fortress Biotech announced FDA approval for ZYCUBO® (copper histidinate) for the treatment of Menkes disease in pediatric patients. As a result of this approval, a Rare Pediatric Disease Priority Review Voucher (PRV) was issued and will be transferred to its majority-owned subsidiary, Cyprium Therapeutics, Inc.
📋 Key Facts
- FDA approved ZYCUBO® (copper histidinate/CUTX-101) for Menkes disease in pediatric patients on January 13, 2026.
- A Rare Pediatric Disease Priority Review Voucher (PRV) was issued following the approval.
- The PRV will be transferred to Cyprium Therapeutics, Inc., a majority-owned subsidiary of Fortress Biotech.
Fortress Biotech entered into a First Amendment to its Credit Agreement with Oaktree Fund Administration, LLC. The amendment extends the loan maturity date to June 30, 2028, modifies the principal repayment schedule, and introduces aggressive revenue-based financial covenants tied to subsidiary Journey Medical Corporation.
🚩 Red Flags
- Aggressive revenue covenants: The Minimum Net Sales Test requires significant quarterly growth in Journey Medical's sales, creating a high risk of default.
- Anti-dilution protection: The warrants include a 'Base Share Price' adjustment (full ratchet), which is highly dilutive to existing shareholders if the stock price drops.
- Repayment pressure: A large portion of the principal (37.5%) becomes due in a single lump sum in March 2028.
📋 Key Facts
- Maturity date extended from July 25, 2027, to June 30, 2028.
- Outstanding loan balance is approximately $29.5 million of a total $35.0 million facility.
- New repayment schedule: 12.5% due Sept/Dec 2027; 37.5% due March 2028; 37.5% due June 2028.
- Introduced 'Minimum Net Sales Test' for subsidiary Journey Medical Corporation, requiring sales to scale from $60M (Dec 2025) up to $80M+ per quarter by Dec 2026.
- Issued warrants to lenders for up to 600,000 shares of common stock at an exercise price of $2.62 per share.
- Warrants include a full ratchet anti-dilution adjustment if the company issues equity at a lower price.
Fortress Biotech announced that the FDA has accepted the resubmission of its New Drug Application (NDA) for CUTX-101 as a Class 1 resubmission. The FDA has set a PDUFA target action date of January 14, 2026.
📋 Key Facts
- FDA accepted the NDA resubmission for CUTX-101 as a Class 1 resubmission on December 15, 2025.
- PDUFA target action date is set for January 14, 2026.
- The filing includes an exhibit containing the full press release (Exhibit 99.1).
Fortress Biotech's subsidiary, Cyprium Therapeutics, announced that Sentynl Therapeutics has resubmitted the New Drug Application (NDA) for CUTX-101 to the FDA. This follows a previous Complete Response Letter issued by the FDA in October 2025.
🚩 Red Flags
- Previous FDA Complete Response Letter (CRL) issued on October 1, 2025, indicating prior regulatory hurdles for the drug candidate.
📋 Key Facts
- Sentynl Therapeutics notified Cyprium on November 14, 2025, that the NDA for CUTX-101 (copper histidinate) has been resubmitted to the FDA.
- CUTX-101 is intended for the treatment of Menkes disease in pediatric patients.
- Cyprium retains ownership of any potential Priority Review Voucher and up to $129 million in aggregate development and sales milestones.
- Sentynl Therapeutics (wholly-owned by Zydus Lifesciences, Ltd.) assumed responsibility for CUTX-101 development from Cyprium in December 2023.
Fortress Biotech, Inc. filed an 8-K to announce its quarterly financial results and provide a corporate update for the period ended September 30, 2025.
📋 Key Facts
- Report date: November 14, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) providing corporate updates and financial results.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Fortress Biotech, Inc. announced that the FDA issued a Complete Response Letter (CRL) for its product candidate CUTX-101 (copper histidinate). This represents a significant regulatory setback for the company's pipeline.
🚩 Red Flags
- Regulatory failure: A CRL indicates the FDA does not currently intend to approve the application in its present form, often requiring additional clinical trials or data.
📋 Key Facts
- FDA issued a Complete Response Letter (CRL) for CUTX-101 (copper histidinate) on October 1, 2025.
- The announcement was made via press release attached as Exhibit 99.1.
- The filing is categorized under Item 8.01 (Other Events).
Fortress Biotech, Inc. filed an 8-K to announce its quarterly financial results for the period ended June 30, 2025. The filing serves as a formal announcement of the corporate update and financial performance release.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Quarter ended June 30, 2025
- The company issued a press release (Exhibit 99.1) containing the corporate update and financial results.
- The information provided is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 liability.
Fortress Biotech reports that AstraZeneca's Phase III clinical program for anselamimab (formerly CAEL-101) failed to meet its primary endpoint of statistical significance in patients with Mayo stages IIIa and IIIb AL amyloidosis. This failure directly impacts Fortress's potential milestone payments from the original Caelum Biosciences acquisition.
🚩 Red Flags
- Failure of a key clinical trial endpoint for a major asset (anselamimab) linked to Fortress via milestone payments.
- Significant uncertainty regarding the $125 million in potential revenue/milestones contingent on regulatory and sales success.
📋 Key Facts
- AstraZeneca announced Phase III CARES program results for anselamimab on July 16, 2025.
- The drug failed to achieve statistical significance for the primary endpoint (time to all-cause mortality and frequency of cardiovascular hospitalizations) in Mayo stages IIIa/IIIb patients.
- Fortress Biotech is eligible for up to $125 million in milestone payments from AstraZeneca based on Caelum's performance.
- AstraZeneca noted 'clinically meaningful improvement' in a prespecified subgroup, but did not characterize the subgroup.
Fortress Biotech, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on June 17, 2025. The meeting included votes for director elections, auditor ratification, executive compensation advisory votes, and an amendment to the Certificate of Incorporation.
📋 Key Facts
- The 2025 Annual Meeting was held virtually on June 17, 2025.
- Seven directors were elected to hold office until the 2026 annual meeting or until resignation/removal.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Shareholders approved a Second Amended and Restated Certificate of Incorporation to provide for officer exculpation.
- The Board determined that 'Say-on-Pay' advisory votes will occur every three years, with the next scheduled vote in 2031.
Fortress Biotech has completed the sale of its subsidiary, Checkpoint Therapeutics, Inc., to Sun Pharmaceutical Industries, Inc. The transaction results in the deconsolidation of Checkpoint and provides Fortress with immediate cash proceeds.
🚩 Red Flags
- Loss of full consolidation of Checkpoint Therapeutics (subsidiary sale).
📋 Key Facts
- Closing Date: May 30, 2025.
- Cash Consideration: Approximately $28.0 million in cash received by Fortress.
- Contingent Value Rights (CVRs): Eligible to receive up to an additional $4.8 million upon achievement of a regulatory milestone.
- Royalty Agreement: Fortress is eligible for quarterly cash payments of 2.5% of net sales of certain products from Checkpoint and Sun Pharma.
- Deconsolidation: Checkpoint Therapeutics will now be a wholly-owned subsidiary of Sun Pharma, not Fortress.
Fortress Biotech, Inc. filed an 8-K to furnish a press release containing a corporate update and financial results for the quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period covered: Quarter ended March 31, 2025
- Purpose of filing: Announcement of financial results and corporate update via press release (Exhibit 99.1)
Dr. Lucy Lu has resigned from the Board of Directors to transition into a new executive role as Chief Strategy Officer, effective April 21, 2025.
📋 Key Facts
- Lucy Lu, M.D., resigned from the Board of Directors effective April 15, 2025.
- Dr. Lu will join the Company as Chief Strategy Officer effective April 21, 2025.
- The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Fortress Biotech, Inc. filed an 8-K to provide a corporate update and announce its financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 31, 2025
- The filing includes a press release (Exhibit 99.1) regarding corporate updates and FY2024 financial results.
- The information provided is furnished but not 'filed' for purposes of Section 18 liability.
Fortress Biotech's majority-controlled subsidiary, Checkpoint Therapeutics, has entered into a definitive merger agreement to be acquired by Sun Pharmaceutical Industries for $4.10 per share in cash and one non-tradable contingent value right (CVR). The deal includes significant milestone-based payments tied to the regulatory approval of cosibelimab in Europe.
🚩 Red Flags
- The CVR is non-tradable, meaning shareholders cannot sell the contingent value component on the open market.
- Significant termination fee of $12.5 million if Checkpoint accepts a superior proposal or if the board withdraws support.
- Complexity of milestone payments: Value fluctuates between $0.20 and $0.70 based on timing and dosing schedule requirements.
📋 Key Facts
- Checkpoint Therapeutics will merge with a subsidiary of Sun Pharmaceutical Industries ('Parent').
- Merger consideration: $4.10 per share in cash plus one non-tradable CVR.
- CVR potential value: Up to $0.70 per share based on regulatory milestones for cosibelimab in the EU/UK.
- Milestone deadline: 36 months after EMA positive validation outcome.
- Termination fee: $12,500,000 payable by Checkpoint under specific circumstances (e.g., superior proposal or board withdrawal).
- Fortress Biotech owns approximately 11.2% of Checkpoint's outstanding shares and has entered into a Support Agreement to vote in favor of the merger.
Fortress Biotech's subsidiary, Cyprium Therapeutics, was notified that the FDA has extended the target action date for the CUTX-101 (Copper Histidinate) New Drug Application to September 30, 2025. Sentynl Therapeutics remains responsible for the development and commercialization of the drug.
🚩 Red Flags
- FDA delay/extension of target action date for a key asset (CUTX-101).
📋 Key Facts
- FDA extended the target action date for the CUTX-101 NDA to September 30, 2025.
- Sentynl Therapeutics is responsible for the development and commercialization of CUTX-101.
- Cyprium retains ownership of any potential Priority Review Voucher (PRV) from the approval.
- Cyprium is eligible to receive royalties and up to $129 million in aggregate milestones.
- Fortress Biotech owns approximately 76% of Cyprium Therapeutics.
Fortress Biotech's majority-owned subsidiary, Cyprium Therapeutics, announced that the FDA has granted priority review for CUTX-101 (Copper Histidinate) with a target action date of June 30, 2025. The filing also clarifies the commercialization structure involving Sentynl Therapeutics.
📋 Key Facts
- FDA accepted the New Drug Application (NDA) for CUTX-101 for priority review.
- Target FDA action date is set for June 30, 2025.
- Sentynl Therapeutics (wholly-owned by Zydus Group) assumed responsibility for development and commercialization in December 2023.
- Cyprium retains ownership of any potential Priority Review Voucher (PRV).
- Fortress/Cyprium is eligible to receive royalties and up to $129 million in aggregate milestones.
- Fortress Biotech owns approximately 76% of Cyprium Therapeutics.
Fortress Biotech's majority-controlled subsidiary, Checkpoint Therapeutics, received FDA approval for UNLOXCYT (cosibelimab-ipdl) to treat adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC). This marks the first and only PD-L1 blocking antibody approved for this specific indication.
📋 Key Facts
- FDA approval granted for UNLOXCYT (cosibelimab-ipdl) on December 13, 2024.
- Indication: Treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) who are not candidates for curative surgery or radiation.
- Approval based on data from Study CK-301-101 (NCT03212404).
- UNLOXCYT is the first and only PD-L1 blocking antibody approved for this indication.
Fortress Biotech, Inc. filed an 8-K to furnish a press release containing its corporate update and financial results for the quarter ended September 30, 2024.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing is for the purpose of providing a corporate update and financial results via Exhibit 99.1.
- Information furnished under Item 2.02 is not considered 'filed' for purposes of Section 18 liability.
Fortress Biotech's majority-controlled subsidiary, Journey Medical Corporation, received FDA approval for Emrosi (Minocycline Hydrochloride Extended Release Capsules) for treating inflammatory lesions of rosacea. The product is expected to be available in the U.S. market by late Q1 or early Q2 2025.
📋 Key Facts
- FDA approved Emrosi™ (DFD-29) for adult inflammatory rosacea lesions.
- Product was developed in collaboration with Dr. Reddy’s Laboratories, Ltd.
- Phase 3 clinical trials met all co-primary and secondary endpoints with no significant safety issues.
- Emrosi demonstrated superiority over standard-of-care (Oracea®) and placebo in reducing inflammatory lesion counts.
- Initial U.S. supply is anticipated for late Q1 or early Q2 2025.
Fortress Biotech completed a multi-pronged financing involving a $6.5 million registered offering of common stock at $1.65 per share and two private placements, including one with the company's CEO. The transactions included the issuance of warrants to investors and the CEO, which will require a resale registration statement.
🚩 Red Flags
- Significant dilution via issuance of nearly 4 million shares plus warrants.
- Related-party transaction: The Chairman, President, and CEO (Lindsay A. Rosenwald, M.D.) participated in a private placement of common stock and warrants.
- Potential for immediate selling pressure upon the effectiveness of the upcoming resale registration statement.
📋 Key Facts
- Registered Offering: 3,939,394 shares of common stock at $1.65 per share (gross proceeds ~$6.5 million).
- Chairman Private Placement: 763,359 shares of common stock at $1.84 per share and warrants at $0.125 per warrant.
- Investor PIPE Warrants: Issued to investors with an exercise price of $1.84 per share.
- Lock-up Agreement: Executives, directors, and >5% holders are locked up for 60 days following the effective date of the resale registration statement.
- Use of Proceeds: General corporate purposes including R&D, clinical trials, and working capital.
Fortress Biotech, Inc. filed an 8-K to provide a corporate update and announce its financial results for the quarter ended June 30, 2024.
📋 Key Facts
- Report date: August 13, 2024
- Reporting period: Quarter ended June 30, 2024
- The filing includes a press release (Exhibit 99.1) containing financial results and corporate updates.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Fortress Biotech entered into a new $50.0 million senior secured credit agreement on July 25, 2024, replacing an existing $60.0 million facility. The deal includes the issuance of warrants to lenders and carries restrictive financial covenants, including mandatory annual equity raises.
🚩 Red Flags
- Restrictive financial covenants: Must maintain minimum liquidity of $7.0 million.
- Revenue-based covenant: Journey Medical Corporation must meet a trailing 12-month net sales target of $50.0 million, tested quarterly.
- Mandatory equity raise requirement: Company must raise common equity or receive monetizations totaling at least $20M (or 50% of annual budget) by the end of each calendar year prior to maturity.
- High interest rate environment (SOFR + 7.625%) and significant prepayment fees/penalties.
- Warrants include full anti-dilution adjustments, including a 'downward' adjustment if shares are issued at a price lower than the warrant exercise price.
📋 Key Facts
- Entered into a $50.0 million senior secured credit agreement with Oaktree Fund Administration, LLC as Agent.
- Borrowed $35.0 million on July 25, 2024; eligible to draw up to an additional $15.0 million.
- Maturity date is July 25, 2027, with a 30-month interest-only period.
- Interest rate: 3-month SOFR + 7.625% (with a 2.50% SOFR floor and 5.75% SOFR cap).
- Lenders received warrants to purchase up to 506,390 shares of common stock at $2.0735 per share.
- Mandatory prepayment required from certain monetization events (e.g., asset sales or priority review vouchers) and dividends >$5M.
Fortress Biotech's subsidiary, Urica Therapeutics, has entered into an agreement to sell the rights and intellectual property of its gout product candidate, dotinurad, to Crystalys Therapeutics. In exchange, Fortress receives a 35% equity stake in Crystalys, a 3% royalty on future net sales, and reimbursement for certain development costs.
🚩 Red Flags
- Asset disposition: The company is divesting a core product candidate (dotinurad) in exchange for equity rather than immediate cash, which may indicate a need to offload development costs/risks or a lack of liquidity to fund the clinical trials independently.
📋 Key Facts
- Urica (subsidiary) sold rights to URAT1 inhibitor 'dotinurad' and related IP to Crystalys Therapeutics.
- Fortress/Urica receives 35% of Crystalys' outstanding equity in exchange for the asset.
- Equity position is protected: Urica cannot be diluted below 15% until Crystalys raises $150 million.
- Agreement includes a 3% securitized royalty on future net sales of dotinurad.
- Urica receives nominal cash reimbursement for certain clinical and development costs.
- Fortress/Urica gains one board seat and one board observer position at Crystalys.
Fortress Biotech has announced a pause in the monthly dividend payments on its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock. This decision is intended to preserve cash, with approximately $0.7 million in monthly obligations being deferred.
🚩 Red Flags
- Suspension of preferred dividend payments is often a precursor to liquidity constraints or significant cash burn concerns.
- Dividends are 'cumulative,' meaning the company's liability increases as unpaid dividends accrue, potentially creating a large future obligation once cash flow improves.
📋 Key Facts
- Dividend amount paused: $0.1953125 per share of 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock.
- Monthly cash savings from pause: approximately $0.7 million.
- Dividends will continue to accrue and cumulate until authorized or declared.
- The Board will revisit the decision based on profitability and cash flow assessments.
Fortress Biotech issued 2,028,345 shares of common stock to former holders of Urica Therapeutics' preferred stock. This issuance satisfies dividend and exchange obligations under a 2022 Dividend Agreement.
🚩 Red Flags
- Dilution of existing shareholders through the issuance of over 2 million new common shares.
📋 Key Facts
- Date of event: June 27, 2024
- Shares issued: 2,028,345 shares of common stock
- Recipient: Former holders of the 8% Cumulative Convertible Class B Preferred Stock of Urica Therapeutics, Inc.
- Purpose: Satisfaction of obligations under a Dividend Payment and Exchange Agreement dated December 27, 2022
- Cash component: $20,747.62 paid for fractional shares and accumulated unpaid dividends
- Registration status: The shares were issued in an exempt transaction but the resale by holders is covered by a registration statement declared effective on June 27, 2024.
Fortress Biotech, Inc. has adopted its Fourth Amended and Restated Bylaws, effective June 19, 2024. The amendments primarily address director election voting requirements and forum selection.
📋 Key Facts
- Board of Directors adopted the Fourth Amended and Restated Bylaws on June 19, 2024.
- Uncontested director elections now require a majority vote of votes cast.
- Contested director elections now require a plurality of votes cast.
- Directors failing to receive a majority in uncontested elections must tender their resignation for Board evaluation.
- Delaware is designated as the exclusive forum for adjudication of disputes.
Fortress Biotech, Inc. reported the results of its 2024 Annual Meeting of Stockholders held on May 23, 2024. Shareholders approved several key proposals including director elections and amendments to various stock incentive plans.
🚩 Red Flags
- Significant increase in share pool (11 million total new shares across Incentive and ESPP plans) which may lead to future dilution for existing shareholders.
📋 Key Facts
- The 2024 Annual Meeting was held via a virtual platform on May 23, 2024.
- Stockholders approved an amendment to the 2013 Stock Incentive Plan to increase common stock issuable by 10,000,000 shares.
- Stockholders approved an amendment to the 2012 Employee Stock Purchase Plan (ESPP) to increase shares issuable by 1,000,000 shares.
- The Amended and Restated Long Term Incentive Plan (LTIP) was extended to July 15, 2035.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Eight directors were elected to hold office until the 2025 annual meeting.
Fortress Biotech, Inc. filed an 8-K to furnish a press release containing its corporate update and financial results for the three months ended March 31, 2024.
📋 Key Facts
- Report date: May 15, 2024
- Reporting period: Three months ended March 31, 2024
- The filing includes a corporate update and financial results via Exhibit 99.1.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Fortress Biotech, Inc. filed an 8-K to provide a corporate update and announce its full-year financial results for the period ended December 31, 2023.
📋 Key Facts
- Report date: March 28, 2024
- Reporting period: Full year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) containing corporate updates and financial results.
- Information is furnished under Item 2.02 but not 'filed' for purposes of Section 18 liability.
Fortress Biotech announced that director Eric Rowinsky, M.D., will not stand for re-election at the 2024 annual meeting due to professional commitments. The departure is not related to any disagreement with the company's operations or policies.
📋 Key Facts
- Dr. Eric Rowinsky informed the company on January 25, 2024, that he will not seek re-election at the 2024 Annual Meeting of Stockholders.
- His service on the Board of Directors will conclude upon the conclusion of the 2024 Annual Meeting.
- The departure is due to 'other professional commitments' and not a disagreement with the company.
- The Company intends to retain Dr. Rowinsky as a consultant following his departure from the Board.
Fortress Biotech, Inc. completed a public offering of 3,303,305 units consisting of common stock and warrants at $3.33 per unit. The company expects to receive approximately $11.0 million in gross proceeds to fund operations and R&D.
🚩 Red Flags
- Dilutive offering: Issuance of 3.3M new shares and warrants will dilute existing shareholders.
- Warrant overhang: Warrants exercisable at $3.21 (slightly below the offering price) create potential future dilution.
📋 Key Facts
- Offered and sold 3,303,305 units (one share of common stock and one warrant per unit).
- Offering price: $3.33 per Unit.
- Warrant exercise price: $3.21 per share.
- Warrants expire five years from issuance.
- Gross proceeds expected: approximately $11.0 million (before fees and expenses).
- Placement agent: Roth Capital Partners, LLC (7.0% commission).
- Closing date: January 3, 2024.